ArticleAmerican journal of translational research2025
Clinical analysis of hospital-acquired infections in patients with multiple myeloma: a study of 200 cases.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical characteristics of hospital-acquired infections (HAIs) in patients undergoing treatment for multiple myeloma.
methodsA retrospective analysis was conducted on 200 patients with multiple myeloma treated at Haiyan County People's Hospital in Jiaxing. The incidence rate, sites of infection, and causative pathogens of HAIs were recorded. Patients were divided into an infection group (n=37) and a non-infection group (n=163) based on the presence of HAIs. According to follow-up outcomes, they were further classified into a recurrence group (n=76) and a non-recurrence group (n=124). Risk factors associated with HAIs in patients with multiple myeloma were analyzed, and the predictive value of serum immunoglobulin A (IgA) and immunoglobulin G (IgG) levels for the recurrence of multiple myeloma was assessed.
resultsAmong the 200 patients with multiple myeloma, the incidence of HAIs was 18.5%. The respiratory tract was the most commonly affected site, with Gram-negative bacilli being the predominant pathogens. Multivariate logistic regression analysis identified neutropenia, age ≥60 years, chemotherapy, low serum albumin levels, high Revised International Staging System (R-ISS) stage, elevated body mass index (BMI), and comorbid diabetes mellitus as significant risk factors for infection following multiple myeloma treatment (all P<0.05). In addition, receiver operating characteristic (ROC) analysis revealed that serum IgA and IgG levels were strong predictors for recurrence in patients with multiple myeloma, with area under the curve (AUC) values of 0.936 and 0.914, respectively. IgA showed a sensitivity of 97.8% and specificity of 93.5%, while IgG demonstrated a sensitivity of 83.3% and specificity of 80.0%.
conclusionPatients with multiple myeloma are at increased risk of developing HAIs after treatment, particularly respiratory infections caused by Gram-negative bacilli. Moreover, serum IgA and IgG levels may serve as reliable biomarkers for predicting disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.